Active Biotech Interim Report Q3 2024
THIRD QUARTER IN BRIEF
- Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1)
- Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)
- Active Biotech reported intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops (September 10)
- Active Biotech announced a rights issue (September 23)
EVENTS AFTER THE END OF THE PERIOD
- Active Biotech adjusts the terms in the announced rights issue (October 2)
FINANCIAL SUMMARY
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2024 2023 | 2024 2023 | 2023 | |||
| Net sales | - | - | - | - | - |
| Operating profit/loss | -8.1 | -10.6 | -29.5 | -33.7 | -46.5 |
| Profit/loss after tax | -8.0 | -10.6 | -29.1 | -33.3 | -45.8 |
| Earnings per share (SEK) | -0.02 | -0.04 | -0.08 | -0.13 | -0.17 |
| Cash and cash equivalents (at close of period) | 6.2 | 5.6 | 36.2 | ||
The report is also available at www.activebiotech.com
The information was submitted for publication, through the agency of the contact persons set out below, at 2024-10-21 22.30 CEST.